Vivos Therapeutics, Inc. (VVOS) — DEF 14A Filings
All DEF 14A filings from Vivos Therapeutics, Inc.. Browse 2 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (2)
-
Vivos Seeks Shareholder Nod for Equity Plan Boost, Director Re-election
— Sep 29, 2025 Risk: medium
Vivos Therapeutics, Inc. (VVOS) is holding its 2025 Annual Meeting of Stockholders on November 4, 2025, as a virtual event. Key proposals include the re-electio -
Vivos Therapeutics Files Definitive Proxy Statement
— Oct 7, 2024 Risk: low
Vivos Therapeutics, Inc. filed a Definitive Proxy Statement (DEF 14A) on October 7, 2024. This filing is a standard disclosure required for public companies, ty
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX